Veranlagung für hohes LDL-Cholesterin
Die Veranlagung für hohe LDL-Cholesterinwerte kann vererbt werden. Unter anderem ist dafür das Gen HMGCR verantwortlich.
Gliederung
Referenzen:
| 1. |
Teslovich TM et. al. (2010) Biological, clinical and population relevance of 95 loci for blood lipids. [^] |
| 2. |
Goldstein JL et. al. (1990) Regulation of the mevalonate pathway. [^] |
| 3. |
Humphries SE et. al. (1985) The isolation, characterisation, and chromosomal assignment of the gene for human 3-hydroxy-3-methylglutaryl coenzyme A reductase, (HMG-CoA reductase). [^] |
| 4. |
None (1987) Conservation of promoter sequence but not complex intron splicing pattern in human and hamster genes for 3-hydroxy-3-methylglutaryl coenzyme A reductase. [^] |
| 5. |
Mohandas T et. al. (1986) Assignment of human 3-hydroxy-3-methylglutaryl coenzyme A reductase gene to q13----q23 region of chromosome 5. [^] |
| 6. |
Osborne TF et. al. (1985) 5' end of HMG CoA reductase gene contains sequences responsible for cholesterol-mediated inhibition of transcription. [^] |
| 7. |
Lindgren V et. al. (1985) Human genes involved in cholesterol metabolism: chromosomal mapping of the loci for the low density lipoprotein receptor and 3-hydroxy-3-methylglutaryl-coenzyme A reductase with cDNA probes. [^] |
| 8. |
Reynolds GA et. al. (1984) HMG CoA reductase: a negatively regulated gene with unusual promoter and 5' untranslated regions. [^] |
| 9. |
Van Doren M et. al. (1998) HMG-CoA reductase guides migrating primordial germ cells. [^] |
| 10. |
Istvan ES et. al. (2001) Structural mechanism for statin inhibition of HMG-CoA reductase. [^] |
| 11. |
Sever N et. al. (2003) Accelerated degradation of HMG CoA reductase mediated by binding of insig-1 to its sterol-sensing domain. [^] |
| 12. |
Wang CY et. al. (2003) Lovastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, induces apoptosis and differentiation in human anaplastic thyroid carcinoma cells. [^] |
| 13. |
Chasman DI et. al. (2004) Pharmacogenetic study of statin therapy and cholesterol reduction. [^] |
| 14. |
None (2004) Genetic polymorphisms and statin therapy. [^] |
| 15. |
Kathiresan S et. al. (2008) Polymorphisms associated with cholesterol and risk of cardiovascular events. [^] |
| 16. |
Aulchenko YS et. al. (2009) Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. [^] |
| 17. |
Yu CY et. al. (2014) HNRNPA1 regulates HMGCR alternative splicing and modulates cellular cholesterol metabolism. [^] |
